北京万泰生物药业股份有限公司 第五届监事会第二十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2023年8月14日以电 子邮件方式向全体监事发出第五届监事会第二十二次会议召开通知和会议材料。 本次会议于2023年8月24日以通讯方式召开。本次会议由公司监事会主席邢庆超 先生主持，应出席监事3人，实际出席监事3人。本次会议的出席人数、召开和表 决方式符合《公司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、监事会会议审议情况 证券代码：603392 证券简称：万泰生物 公告编号：2023-055 （2）公司2023年半年度报告的内容和格式符合中国证监会和证券交易所的 各项规定，所包含的信息能从各个方面真实、准确、完整地反映出公司2023年半 年度的经营管理和财务状况。 （3）在提出本意见前，未发现参与2023年半年度报告编制和审议的人员有 违反保密规定的行为。 具体内容详见公司于指定信息披露媒体披露的公司2023年半年度报告全 ...

董事、监事和高级管理人员所持公司股 份及其变动管理制度 $$\exists{0}\exists\exists{\notin{J}}{\backslash J}$$ 北京万泰生物药业股份有限公司 董事、监事和高级管理人员所持公司股份及其变动管理制度 北京万泰生物药业股份有限公司 北京万泰生物药业股份有限公司 董事、监事和高级管理人员所持公司股份及其变动管理制度 第二条 公司董事、监事和高级管理人员在买卖本公司股票及其衍生品种前， 应知悉《公司法》《证券法》等法律、法规、规范性文件关于内幕交易、短线交 易、操纵市场等禁止行为的规定，不得进行违法违规的交易。 第三条 公司董事、监事和高级管理人员所持公司股份，是指登记在其名下 的所有本公司股份；公司董事、监事和高级管理人员从事融资融券交易的，还包 括记载在其信用账户内的本公司股份；公司董事、监事、高级管理人员委托他人 代行买卖股票，视作本人所为，也应遵守本制度并履行相关询问和报告义务。 第四条 本公司董事、监事和高级管理人员可以持有和变动所持本公司股份， 但应遵守法律法规、监管机构以及本办法的相关规定，对持股比例、持股期限、 减持方式、减持价格做出承诺的，应当严格履 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,886,602,037.70, representing a decrease of 8.98% compared to the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was RMB 1,244,917,930.85, down 6.46% year-on-year[4]. - The diluted earnings per share for Q1 2023 was RMB 1.38, reflecting a decline of 8.61%[1]. - Total revenue for Q1 2023 was CNY 2,886,602,037.70, a decrease of 9.0% compared to CNY 3,171,223,475.09 in Q1 2022[20]. - Operating profit for Q1 2023 was CNY 1,433,596,712.00, down from CNY 1,631,731,632.61 in Q1 2022, reflecting a decline of 12.1%[21]. - Net profit for Q1 2023 was CNY 1,252,742,514.19, compared to CNY 1,386,767,882.04 in Q1 2022, representing a decrease of 9.7%[21]. - Basic earnings per share for Q1 2023 were CNY 1.38, down from CNY 1.51 in Q1 2022, a decrease of 8.6%[22]. Cash Flow and Investments - The net cash flow from operating activities was negative RMB 313,683,356.17, a significant decrease of 170.00% compared to the previous year[4]. - In Q1 2023, the cash inflow from operating activities was CNY 1,705,154,373.92, compared to CNY 1,678,729,660.33 in Q1 2022, reflecting a slight increase[23]. - The net cash flow from operating activities in Q1 2023 was CNY -313,683,356.17, a decrease from CNY 448,101,537.24 in Q1 2022[23]. - Cash inflow from investment activities totaled CNY 1,142,095,641.03 in Q1 2023, significantly up from CNY 12,499,574.70 in Q1 2022[24]. - The net cash flow from investment activities was CNY -481,231,342.96 in Q1 2023, worsening from CNY -296,359,100.14 in Q1 2022[24]. - Cash inflow from financing activities was CNY 25,519,500.00 in Q1 2023, down from CNY 120,000,000.00 in Q1 2022[24]. - The net cash flow from financing activities was CNY -23,898,209.58 in Q1 2023, compared to CNY 46,054,986.29 in Q1 2022[24]. - The company reported a significant increase in cash outflow for operating activities, totaling CNY 2,018,837,730.09 in Q1 2023, compared to CNY 1,230,628,123.09 in Q1 2022[23]. - The cash outflow for investment activities in Q1 2023 was CNY 1,623,326,983.99, compared to CNY 308,858,674.84 in Q1 2022, indicating increased investment spending[24]. - The company experienced a net decrease in cash and cash equivalents of CNY 821,899,852.16 in Q1 2023, contrasting with an increase of CNY 192,570,932.27 in Q1 2022[24]. Assets and Liabilities - Total assets at the end of Q1 2023 were RMB 17,253,876,518.46, an increase of 6.31% from the end of the previous year[6]. - Total assets as of March 31, 2023, amounted to CNY 17,253,876,518.46, an increase from CNY 16,229,516,571.12 at the end of 2022[18]. - Current assets totaled CNY 12,919,449,862.76 as of March 31, 2023, compared to CNY 12,179,759,105.13 at the end of 2022, indicating a growth of 6.1%[18]. - The company's cash and cash equivalents decreased to CNY 4,371,171,076.64 from CNY 5,192,247,920.74, a decline of 15.8%[18]. - Total liabilities decreased to CNY 3,476,242,147.29 from CNY 3,664,624,714.14, reflecting a reduction of 5.2%[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,142[11]. - The largest shareholder, Yangshengtang Co., Ltd., held 55.64% of the shares, totaling 504,148,520 shares[11]. Research and Development - The company incurred RMB 71 million in research and development expenses related to the nasal spray COVID-19 vaccine, which were fully expensed this quarter[6]. - Research and development expenses increased significantly to CNY 217,843,428.15 in Q1 2023, up from CNY 106,310,269.96 in Q1 2022, marking a rise of 104.0%[20]. Credit Impairment - The company reported a significant credit impairment loss of CNY -69,527,051.75 in Q1 2023, compared to CNY -82,611,533.09 in Q1 2022[20].

证券代码：603392 证券简称：万泰生物 公告编号：2023-036 北京万泰生物药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 4 月 27 日(星期四)下午 16:00-17:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （一） 会议召开时间：2023 年 4 月 27 日下午 16:00-17:00 （二） 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络互动 三、参加人员 董事长兼总经理：邱子欣先生（代行董事会秘书） 独立董事：赵治纲先生 投资者可于 2023 年 4 月 20 日(星期四)至 4 月 26 日(星期三)16:00 前登 录上证路演中心网站首页 ...

Financial Performance - The net profit attributable to the parent company for 2022 was CNY 1,437,901,441.50, while the consolidated net profit attributable to shareholders of the listed company was CNY 4,735,795,243.51[4]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% growth compared to the previous year[13]. - In 2022, the company's operating revenue reached ¥11,185,188,715.34, representing a year-over-year increase of 94.51% compared to ¥5,750,329,074.69 in 2021[20]. - The net profit attributable to shareholders was ¥4,735,795,243.51 in 2022, up 134.28% from ¥2,021,467,667.66 in 2021[20]. - The net cash flow from operating activities increased by 145.70% to ¥4,132,592,572.73 in 2022, compared to ¥1,681,947,606.84 in 2021[20]. - Basic earnings per share rose to ¥5.31 in 2022, a significant increase of 130.87% from ¥2.30 in 2021[21]. - The company's total assets grew by 130.34% to ¥16,229,516,571.12 at the end of 2022, compared to ¥7,045,948,104.34 at the end of 2021[20]. - The net assets attributable to shareholders increased by 176.32% to ¥12,341,257,272.74 at the end of 2022, up from ¥4,466,287,176.41 at the end of 2021[20]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 10 per 10 shares (including tax) and to convert 4 shares from capital reserves for every 10 shares held[4]. - The total number of shares eligible for dividend distribution is 904,485,385, resulting in a total cash dividend distribution of CNY 904,485,385.00 (including tax)[4]. - The cash dividend accounts for 100% of the profit distribution for the period, representing 76.83% of the net profit of the parent company and 23.33% of the consolidated net profit attributable to ordinary shareholders[4]. - The company repurchased shares amounting to CNY 200,167,849.00 during the reporting period, which will be included in the total profit distribution calculation[4]. Research and Development - Investment in R&D increased by 30%, focusing on the development of new vaccines and diagnostic products[13]. - The company has a strong R&D team and has invested significantly in innovation, ensuring continuous product development and technological advancement[56]. - The company is focusing on the development of third-generation vaccines, including recombinant subunit vaccines and mRNA vaccines[52]. - The company has established several research centers in collaboration with universities and health organizations to enhance its R&D capabilities[108]. - The company is actively pursuing new product development and market expansion strategies to strengthen its competitive position in the diagnostics industry[101][102]. Market Expansion and Product Development - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[13]. - A strategic acquisition of a local biotech firm was completed, expected to enhance the company's product portfolio and market reach[13]. - The company is focusing on expanding its presence in international markets, with new product registrations in countries like Nepal and Morocco for its HPV vaccine[102]. - The company is actively introducing advanced international testing technologies into China, including partnerships with foreign companies for diagnostic reagent development[46]. - The company aims to launch several new vaccines within the next 5 to 10 years, including the varicella vaccine, 9-valent HPV vaccine, and 20-valent pneumococcal vaccine, among others[136]. Compliance and Governance - The company received a standard unqualified audit report from Rongcheng Accounting Firm[3]. - The board of directors and senior management have confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[5]. - The company strictly adheres to the requirements of the Company Law, Securities Law, and other relevant regulations to enhance information disclosure and improve corporate governance structure[152]. - The supervisory board ensures compliance and legality in the company's financial and operational activities, fulfilling its responsibilities diligently[153]. Environmental Responsibility - The company invested 1,000,000 RMB in environmental protection during the reporting period[190]. - The wastewater treatment facility has a capacity of 500 m³/d and meets the discharge standards for pollutants[192]. - The company has established an emergency response plan for environmental incidents, which was filed with the ecological environment bureau[194]. - The company has implemented effective noise reduction measures in its facilities, minimizing the impact of noise pollution from equipment such as gas boilers and air conditioning units[199]. - The company has not faced any legal penalties for environmental violations, demonstrating compliance with environmental regulations[200]. Employee and Management Structure - The company employed 4,016 staff as of December 31, 2022, an increase of 913 from the previous year, with 1,259 in R&D roles[44]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to CNY 10.2361 million[163]. - The company has a diverse management team with extensive experience in various sectors, enhancing its operational capabilities[161]. - The company emphasizes the importance of performance-based remuneration to align the interests of management with those of shareholders[163]. - The company has established a training management standard to enhance employee skills and knowledge[179].